谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

A Phase 2 Open-Label Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (EMPOWER-CSCC-1): Final Long-Term Analysis of Groups 1, 2, and 3, and Primary Analysis of Fixed-Dose Treatment Group 6

Brett G. M. Hughes,Alexander Guminski,Samantha Bowyer,Michael R. Migden,Chrysalyne D. Schmults,Nikhil I. Khushalani,Anne Lynn S. Chang,Jean-Jacques Grob,Karl D. Lewis,George Ansstas,Fiona Day,Rahul Ladwa,Brian N. Stein,Eva Munoz Couselo,Friedegund Meier,Axel Hauschild,Dirk Schadendorf,Nicole Basset-Seguin,Badri Modi,Sophie Dalac-Rat,Lara A. Dunn,Lukas Flatz,Laurent Mortier, Sarah Guegan,Lucie M. Heinzerling,Janice M. Mehnert,Sabiha Trabelsi,Ainara Soria-Rivas,Alexander J. Stratigos,Claas Ulrich,Deborah J. Wong, Marie Beylot-Barry,Paolo Bossi, Cristina Buges Sanchez,Sunandana Chandra,Caroline Robert,Jeffery S. Russell,Ann W. Silk,Jocelyn Booth,Suk-Young Yoo,Frank Seebach,Israel Lowy,Matthew G. Fury,Danny Rischin

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2025）

引用 0|浏览12
关键词
advanced cutaneous squamous cell carcinoma,cemiplimab,clinical trials,fixed dose,immunotherapy,skin cancer,skin neoplasms
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要